Owlstone Medical, Actelion team up for pulmonary hypertension detection
Currently, early diagnosis of PH is very difficult and a delay of years between the onset of symptoms and diagnosis and treatment is unfortunately common.
Read More
Tag: Actelion
NHS England to fund Actelion’s Uptravi
Actelion Pharmaceuticals has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH), can now be treated with Uptravi.
Read More
Actelion’s Opsumit shows promise in portopulmonary hypertension
Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary target.
Read More
PAH patients in England denied access to Actelion’s Uptravi on NHS
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Read More
Wales backs NHS use of Actelion’s Uptravi for PAH
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read More
EU clears J&J’s Actelion buy, with conditions
The European Commission has issued a conditional green light for Johnson & Johnson’s planned $30 billion purchase of Actelion, laying out the commitments it feels are necessary to ensure that clinical development of the firms’ innovative insomnia drugs will not be adversely affected by the merger.
Read More
EU safety review backs continued use Uptravi for PAH
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat patients with pulmonary arterial hypertension, a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs.
Read More
EU nod for Actelion’s rare immune system cancer drug
Actelion has bagged European Union Approval for Ledaga, its treatment for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare potentially life-threatening immune system cancer that appears in the skin.
Read More
EU regulators allow use of Uptravi during safety review
European regulators are advising that doctors can continue prescribing Actelion’s Uptravi for pulmonary arterial hypertension while an investigation into its safety is completed.
Read More
J&J shells out $30 billion on Actelion
Johnson & Johnson and Actelion have announced a $30 billion merger that will see the latter’s R&D unit spun out into a separate business, ending months of speculation.
Read More
Actelion’s PAH drug fails to hit target in PhIII study
Actelion has suffered a setback in its quest to expand the uses of Tracleer follow-up Opsumit, after a study assessing the drug in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Read More
J&J walks away from Actelion deal talks
Johnson & Johnson has bowed out of a potential merger with Actelion, opening up the field for an unconfirmed contender widely believed to be French drugmaker Sanofi.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
